New medications are offering promising advancements in the fight against obesity, a growing global health crisis linked to numerous chronic diseases. While drugs like semaglutide and tirzepatide have shown important results in weight management, a new meta-analysis reveals a critical challenge: weight regain is common after stopping treatment, and occurs at a rate faster than with traditional diet and exercise. Experts emphasize that these medications are best utilized as part of a long-term, medically supervised strategy alongside lifestyle changes, and are not a standalone solution.
Obesity is far more than a cosmetic concern; it’s a significant health risk and a breeding ground for numerous diseases. The condition is on the rise globally and is increasingly viewed as a potential epidemic of the 21st century, prompting extensive medical research into effective treatments. Recent advancements suggest we may be closer to tackling this challenge than ever before, thanks to a new class of drugs known as GLP-1 agonists – including semaglutide (Ozempic or Wegovy), liraglutide (Victoza or Saxenda), and tirzepatide (Mounjaro or Zepbound), the latter of which is a dual GLP-1/GIP agonist.
Further breakthroughs are on the horizon with a new generation of obesity medications poised to revolutionize treatment. These medications are designed to be taken orally, daily, and offer a more accessible alternative to injections. “The new GLP-1 medications have marked a turning point in the management of obesity, and 2026 will be a decisive year,” explains Cristóbal Morales, an endocrinologist and nutritionist, and member of the Spanish Society for the Study of Obesity (Seedo). “The major innovation is the arrival of daily oral GLP-1 agonists, which offer similar efficacy to injections but with improved accessibility and adherence. These new drugs will play a crucial role in maintaining weight loss, as the goal is long-term management.” Morales adds that another significant development could be advanced hormonal combinations, uniting GLP-1 with other hormones to achieve weight loss exceeding 21% and improved metabolic benefits. Researchers also anticipate a triple therapy combination of peptides, potentially leading to weight loss surpassing 28% – an unprecedented result – by the end of 2026.
These Drugs Aren’t a Quick Fix
Despite the promising advancements, experts caution that these medications are not a magic bullet. A recent meta-analysis published in the British Medical Journal, reviewing 37 international studies, found that weight regain occurs in less than two years after stopping these drugs. This regain is accompanied by a return of cardiovascular and metabolic risks associated with obesity, such as high cholesterol, high blood pressure, and diabetes. Perhaps most concerning, the study revealed that weight recovery after discontinuing these medications is nearly four times faster than after making changes to diet or exercise.
Experts explain that these drugs artificially alter the body’s weight regulation system. “Obesity medications artificially modify the body’s weight regulation system: they reduce hunger, increase feelings of fullness, and make it easier to eat less without requiring deep behavioral learning,” explains Montse Prados, an endocrinologist, author of “The Medicine You Need is You,” and member of the Obesity group of the Spanish Society of Endocrinology and Nutrition (SEEN). “When they are stopped, that ‘pharmacological scaffolding’ disappears abruptly, and the biological system returns to its previous state.”
The meta-analysis showed that, after stopping these new drugs, weight is regained at an average rate of 0.4 kg/month, increasing to 0.8 kg/month with the most potent medications, with a return to baseline weight occurring around 18 months. “This is because weight loss induced by drugs activates the same adaptive mechanisms as any weight loss, but without the person necessarily developing compensatory behavioral strategies,” Prados explains. “While the drug is present, these mechanisms are ‘masked,’ but when it is removed, they all emerge at once, favoring rapid recovery.”
Strategies to Prevent Weight Regain
Given these findings, understanding strategies to prevent weight regain is crucial. Prados recommends “losing weight at a progressive pace, preserving muscle mass (by consuming protein and doing strength training), re-educating appetite and hunger signals, and engaging in emotional and behavioral work, using the drug as a tool, not the only solution.” The study also found that behavioral support does not improve recovery after stopping the drug. The meta-analysis showed that neither behavioral support during treatment nor after stopping it modifies the speed of weight recovery. “The reason is clear: the relapse is primarily biological, not educational or volitional,” Prados notes.
Therefore, experts emphasize that obesity should be treated as a chronic illness. The new drugs require prolonged or intermittent use, and behavioral approaches are necessary, but cannot replace the body’s physiology. Morales adds that “these drugs should always be used under medical supervision, with strict control by a specialist, accompanied by a comprehensive approach that includes lifestyle and dietary changes.”
